{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:30:00Z","timestamp":1792812600766,"version":"4.5.0"},"reference-count":87,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2018.0419","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T14:47:13Z","timestamp":1529419633000},"source":"Crossref","is-referenced-by-count":29,"title":["The Diagnosis and Treatment of Primary CNS Lymphoma"],"prefix":"10.3238","author":[{"given":"Louisa","family":"von Baumgarten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Illerhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Korfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Deckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2018,6,22]]},"reference":[{"key":"10.3238\/arztebl.2018.0419_ref1","doi-asserted-by":"crossref","unstructured":"Korfel A, Schlegel U: Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 2013; 9: 317\u201327","DOI":"10.1038\/nrneurol.2013.83"},{"key":"10.3238\/arztebl.2018.0419_ref2","doi-asserted-by":"crossref","unstructured":"Hoang-Xuan K, Bessell E, Bromberg J, et al.: Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 2015; 16: e322\u201332","DOI":"10.1016\/S1470-2045(15)00076-5"},{"key":"10.3238\/arztebl.2018.0419_ref3","doi-asserted-by":"crossref","unstructured":"Deckert M, Brunn A, Montesinos-Rongen M, Terreni MR, Ponzoni M: Primary lymphoma of the central nervous system\u2014a diagnostic challenge. Hematol Oncol 2014; 32: 57\u201367","DOI":"10.1002\/hon.2087"},{"key":"10.3238\/arztebl.2018.0419_ref4","doi-asserted-by":"crossref","unstructured":"Louis DN, Perry A, Reifenberger G, et al.: The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131: 803\u201320","DOI":"10.1007\/s00401-016-1545-1"},{"key":"10.3238\/arztebl.2018.0419_ref5","doi-asserted-by":"crossref","unstructured":"Hoffman S, Propp JM, McCarthy BJ: Temporal trends in incidence of primary brain tumors in the United States, 1985\u20131999. Neuro Oncol 2006; 8: 27\u201337","DOI":"10.1215\/S1522851705000323"},{"key":"10.3238\/arztebl.2018.0419_ref6","doi-asserted-by":"crossref","unstructured":"Shiels MS, Pfeiffer RM, Besson C, et al.: Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol 2016; 174: 417\u201324","DOI":"10.1111\/bjh.14073"},{"key":"10.3238\/arztebl.2018.0419_ref7","doi-asserted-by":"crossref","unstructured":"Mendez JS, Ostrom QT, Gittleman H, et al.: The elderly left behind\u2014changes in survival trends of primary central nervous system lymphoma over the past four decades. Neuro Oncol 2018; 20:687\u201394","DOI":"10.1093\/neuonc\/nox187"},{"key":"10.3238\/arztebl.2018.0419_ref8","doi-asserted-by":"crossref","unstructured":"Deckert M, Engert A, Bruck W, et al.: Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia 2011; 25: 1797\u2013807","DOI":"10.1038\/leu.2011.169"},{"key":"10.3238\/arztebl.2018.0419_ref9","doi-asserted-by":"crossref","unstructured":"Kasenda B, Ferreri AJ, Marturano E, et al.: First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)\u2014a systematic review and individual patient data meta-analysis. Ann Oncol 2015; 7: 1305\u201313","DOI":"10.1093\/annonc\/mdv076"},{"key":"10.3238\/arztebl.2018.0419_ref10","doi-asserted-by":"crossref","unstructured":"Kuker W, Nagele T, Korfel A, et al.: Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 2005; 72: 169\u201377","DOI":"10.1007\/s11060-004-3390-7"},{"key":"10.3238\/arztebl.2018.0419_ref11","doi-asserted-by":"crossref","unstructured":"Buhring U, Herrlinger U, Krings T, Thiex R, Weller M, Kuker W: MRI features of primary central nervous system lymphomas at presentation. Neurology 2001; 57: 393\u20136","DOI":"10.1212\/WNL.57.3.393"},{"key":"10.3238\/arztebl.2018.0419_ref12","doi-asserted-by":"crossref","unstructured":"Lai R, Rosenblum MK, DeAngelis LM: Primary CNS lymphoma: a whole-brain disease? Neurology 2002; 59: 1557\u201362","DOI":"10.1212\/01.WNL.0000034256.20173.EA"},{"key":"10.3238\/arztebl.2018.0419_ref13","doi-asserted-by":"crossref","unstructured":"Pirotte B, Levivier M, Goldman S, Brucher JM, Brotchi J, Hildebrand J: Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and review of the literature. J Neurooncol 1997; 32: 63\u20139","DOI":"10.1023\/A:1005733416571"},{"key":"10.3238\/arztebl.2018.0419_ref14","doi-asserted-by":"crossref","unstructured":"Mathew BS, Carson KA, Grossman SA: Initial response to glucocorticoids. Cancer 2006; 106: 383\u20137","DOI":"10.1002\/cncr.21583"},{"key":"10.3238\/arztebl.2018.0419_ref15","unstructured":"Bruck W, Brunn A, Klapper W, et al.: [Differential diagnosis of lymphoid infiltrates in the central nervous system: experience of the network lymphomas and lymphomatoid lesions in the nervous system]. Pathologe 2013; 34: 186\u201397"},{"key":"10.3238\/arztebl.2018.0419_ref16","doi-asserted-by":"crossref","unstructured":"Kreth FW, Muacevic A, Medele R, Bise K, Meyer T, Reulen HJ: The risk of haemorrhage after image guided stereotactic biopsy of intra-axial brain tumours\u2014 a prospective study. Acta Neurochir (Wien) 2001; 143: 539\u201345; discussion 45\u20136","DOI":"10.1007\/s007010170058"},{"key":"10.3238\/arztebl.2018.0419_ref17","doi-asserted-by":"crossref","unstructured":"Royer-Perron L, Hoang-Xuan K, Alentorn A: Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies? Curr Opin Neurol 2017; 30: 669\u201376","DOI":"10.1097\/WCO.0000000000000492"},{"key":"10.3238\/arztebl.2018.0419_ref18","doi-asserted-by":"crossref","unstructured":"Porter AB, Giannini C, Kaufmann T, et al.: Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma. Ann Neurol 2008; 63: 662\u20137","DOI":"10.1002\/ana.21366"},{"key":"10.3238\/arztebl.2018.0419_ref19","doi-asserted-by":"crossref","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ, et al.: Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034\u201343","DOI":"10.1200\/JCO.2005.13.524"},{"key":"10.3238\/arztebl.2018.0419_ref20","doi-asserted-by":"crossref","unstructured":"Ferreri AJ, Reni M, Zoldan MC, Terreni MR, Villa E: Importance of complete staging in non-hodgkin\u2018s lymphoma presenting as a cerebral mass lesion. Cancer 1996; 77: 827\u201333","DOI":"10.1002\/(SICI)1097-0142(19960301)77:5<827::AID-CNCR4>3.0.CO;2-B"},{"key":"10.3238\/arztebl.2018.0419_ref21","doi-asserted-by":"crossref","unstructured":"Jahnke K, Hummel M, Korfel A, et al.: Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol 2006; 24: 4754\u20137","DOI":"10.1200\/JCO.2006.06.7165"},{"key":"10.3238\/arztebl.2018.0419_ref22","doi-asserted-by":"crossref","unstructured":"Brunn A, Nagel I, Montesinos-Rongen M, et al.: Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. Acta Neuropathol 2013; 126: 603\u20135","DOI":"10.1007\/s00401-013-1169-7"},{"key":"10.3238\/arztebl.2018.0419_ref23","doi-asserted-by":"crossref","unstructured":"Montesinos-Rongen M, Schafer E, Siebert R, Deckert M: Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. Acta Neuropathol 2012; 124: 905\u20136","DOI":"10.1007\/s00401-012-1064-7"},{"key":"10.3238\/arztebl.2018.0419_ref24","doi-asserted-by":"crossref","unstructured":"Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M: Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 2011; 122: 791\u20132","DOI":"10.1007\/s00401-011-0891-2"},{"key":"10.3238\/arztebl.2018.0419_ref25","doi-asserted-by":"crossref","unstructured":"Montesinos-Rongen M, Schmitz R, Brunn A, et al.: Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. Acta Neuropathol 2010; 120: 529\u201335","DOI":"10.1007\/s00401-010-0709-7"},{"key":"10.3238\/arztebl.2018.0419_ref26","doi-asserted-by":"crossref","unstructured":"Ferreri AJ, Blay JY, Reni M, et al.: Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol 2003; 21: 266\u201372","DOI":"10.1200\/JCO.2003.09.139"},{"key":"10.3238\/arztebl.2018.0419_ref27","doi-asserted-by":"crossref","unstructured":"Weller M, Martus P, Roth P, Thiel E, Korfel A, German PCNSL Study Group: Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 2012; 14: 1481\u20134","DOI":"10.1093\/neuonc\/nos159"},{"key":"10.3238\/arztebl.2018.0419_ref28","doi-asserted-by":"crossref","unstructured":"Grommes C, DeAngelis LM: Primary CNS lymphoma. J Clin Oncol 2017; 35: 2410\u20138","DOI":"10.1200\/JCO.2017.72.7602"},{"key":"10.3238\/arztebl.2018.0419_ref29","doi-asserted-by":"crossref","unstructured":"Jahnke K, Korfel A, Martus P, et al.: High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 2005; 16: 445\u20139","DOI":"10.1093\/annonc\/mdi075"},{"key":"10.3238\/arztebl.2018.0419_ref30","doi-asserted-by":"crossref","unstructured":"Ferreri AJ, Reni M, Foppoli M, et al.: High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374: 1512\u201320","DOI":"10.1016\/S0140-6736(09)61416-1"},{"key":"10.3238\/arztebl.2018.0419_ref31","doi-asserted-by":"crossref","unstructured":"Cobert J, Hochberg E, Woldenberg N, Hochberg F: Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort. J Neurooncol 2010; 98: 385\u201393","DOI":"10.1007\/s11060-009-0090-3"},{"key":"10.3238\/arztebl.2018.0419_ref32","doi-asserted-by":"crossref","unstructured":"Bergner N, Monsef I, Illerhaus G, Engert A, Skoetz N: Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Cochrane Database Syst Rev 2012; 11: CD009355","DOI":"10.1002\/14651858.CD009355.pub2"},{"key":"10.3238\/arztebl.2018.0419_ref33","doi-asserted-by":"crossref","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E, et al.: Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016; 3: e217\u201327","DOI":"10.1016\/S2352-3026(16)00036-3"},{"key":"10.3238\/arztebl.2018.0419_ref34","doi-asserted-by":"crossref","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, et al.: Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the international extranodal lymphoma study group-32 phase 2 trial. Lancet Haematol 2017; 4: e510\u201323","DOI":"10.1016\/S2352-3026(17)30174-6"},{"key":"10.3238\/arztebl.2018.0419_ref35","doi-asserted-by":"crossref","unstructured":"Nelson DF: Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol 1999; 43: 241\u20137","DOI":"10.1023\/A:1006206602918"},{"key":"10.3238\/arztebl.2018.0419_ref36","doi-asserted-by":"crossref","unstructured":"DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ, Radiation Therapy Oncology Group Study: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93\u201310. J Clin Oncol 2002; 20: 4643\u20138","DOI":"10.1200\/JCO.2002.11.013"},{"key":"10.3238\/arztebl.2018.0419_ref37","doi-asserted-by":"crossref","unstructured":"Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al.: High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003; 21: 4483\u20138","DOI":"10.1200\/JCO.2003.03.108"},{"key":"10.3238\/arztebl.2018.0419_ref38","doi-asserted-by":"crossref","unstructured":"Korfel A, Martus P, Nowrousian MR, et al.: Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma. Br J Haematol 2005; 128: 177\u201383","DOI":"10.1111\/j.1365-2141.2004.05284.x"},{"key":"10.3238\/arztebl.2018.0419_ref39","doi-asserted-by":"crossref","unstructured":"Glass J, Won M, Schultz CJ, et al.: Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227. J Clin Oncol 2016; 34: 1620\u20135","DOI":"10.1200\/JCO.2015.64.8634"},{"key":"10.3238\/arztebl.2018.0419_ref40","doi-asserted-by":"crossref","unstructured":"Morris PG, Correa DD, Yahalom J, et al.: Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 2013; 31: 3971\u20139","DOI":"10.1200\/JCO.2013.50.4910"},{"key":"10.3238\/arztebl.2018.0419_ref41","doi-asserted-by":"crossref","unstructured":"Thiel E, Korfel A, Martus P, et al.: High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11: 1036\u201347","DOI":"10.1016\/S1470-2045(10)70229-1"},{"key":"10.3238\/arztebl.2018.0419_ref42","doi-asserted-by":"crossref","unstructured":"Abrey LE, DeAngelis LM, Yahalom J: Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859\u201363","DOI":"10.1200\/JCO.1998.16.3.859"},{"key":"10.3238\/arztebl.2018.0419_ref43","doi-asserted-by":"crossref","unstructured":"Kasenda B, Loeffler J, Illerhaus G, Ferreri AJ, Rubenstein J, Batchelor TT: The role of whole brain radiation in primary CNS lymphoma. Blood 2016; 128: 32\u20136","DOI":"10.1182\/blood-2016-01-650101"},{"key":"10.3238\/arztebl.2018.0419_ref44","doi-asserted-by":"crossref","unstructured":"Correa DD, Shi W, Abrey LE, et al.: Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol 2012; 14: 101\u20138","DOI":"10.1093\/neuonc\/nor186"},{"key":"10.3238\/arztebl.2018.0419_ref45","doi-asserted-by":"crossref","unstructured":"Doolittle ND, Korfel A, Lubow MA, et al.: Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology 2013; 81: 84\u201392","DOI":"10.1212\/WNL.0b013e318297eeba"},{"key":"10.3238\/arztebl.2018.0419_ref46","doi-asserted-by":"crossref","unstructured":"Hoang-Xuan K, Taillandier L, Chinot O, et al.: Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003; 21: 2726\u201331","DOI":"10.1200\/JCO.2003.11.036"},{"key":"10.3238\/arztebl.2018.0419_ref47","doi-asserted-by":"crossref","unstructured":"Herrlinger U, Schafer N, Fimmers R, et al.: Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. J Cancer Res Clin Oncol. 2017; 143:1815\u201321","DOI":"10.1007\/s00432-017-2423-5"},{"key":"10.3238\/arztebl.2018.0419_ref48","doi-asserted-by":"crossref","unstructured":"Rubenstein JL, Hsi ED, Johnson JL, et al.: Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013; 31: 3061\u20138","DOI":"10.1200\/JCO.2012.46.9957"},{"key":"10.3238\/arztebl.2018.0419_ref49","doi-asserted-by":"crossref","unstructured":"Pels H, Schmidt-Wolf IG, Glasmacher A, et al.: Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003; 21: 4489\u201395","DOI":"10.1200\/JCO.2003.04.056"},{"key":"10.3238\/arztebl.2018.0419_ref50","doi-asserted-by":"crossref","unstructured":"Juergens A, Pels H, Rogowski S, et al.: Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010; 67: 182\u20139","DOI":"10.1002\/ana.21824"},{"key":"10.3238\/arztebl.2018.0419_ref51","doi-asserted-by":"crossref","unstructured":"Pels H, Juergens A, Glasmacher A, et al.: Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol 2009; 91: 299\u2013305","DOI":"10.1007\/s11060-008-9712-4"},{"key":"10.3238\/arztebl.2018.0419_ref52","doi-asserted-by":"crossref","unstructured":"Illerhaus G, Kasenda B, Ihorst G, et al.: High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol 2016; 3: e388\u201397.","DOI":"10.1016\/S2352-3026(16)30050-3"},{"key":"10.3238\/arztebl.2018.0419_ref53","doi-asserted-by":"crossref","unstructured":"Illerhaus G, Marks R, Ihorst G, et al.: High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24: 3865\u201370","DOI":"10.1200\/JCO.2006.06.2117"},{"key":"10.3238\/arztebl.2018.0419_ref54","doi-asserted-by":"crossref","unstructured":"Omuro A, Correa DD, DeAngelis LM, et al.: R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 2015; 125: 1403\u201310","DOI":"10.1182\/blood-2014-10-604561"},{"key":"10.3238\/arztebl.2018.0419_ref55","doi-asserted-by":"crossref","unstructured":"Schorb E, Finke J, Ferreri AJ, et al.: High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma\u2014a randomized phase III trial (MATRix). BMC Cancer 2016; 16: 282","DOI":"10.1186\/s12885-016-2311-4"},{"key":"10.3238\/arztebl.2018.0419_ref56","doi-asserted-by":"crossref","unstructured":"Langner-Lemercier S, Houillier C, Soussain C, et al.: Primary CNS lymphoma at first relapse\/progression: characteristics, management, and outcome of 256 patients from the French LOC Network. Neuro Oncol 2016; 18: 1297\u2013303","DOI":"10.1093\/neuonc\/now033"},{"key":"10.3238\/arztebl.2018.0419_ref57","doi-asserted-by":"crossref","unstructured":"Jahnke K, Thiel E, Martus P, et al.: Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol 2006; 80: 159\u201365","DOI":"10.1007\/s11060-006-9165-6"},{"key":"10.3238\/arztebl.2018.0419_ref58","doi-asserted-by":"crossref","unstructured":"Plotkin SR, Betensky RA, Hochberg FH, et al.: Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004; 10: 5643\u20136","DOI":"10.1158\/1078-0432.CCR-04-0159"},{"key":"10.3238\/arztebl.2018.0419_ref59","doi-asserted-by":"crossref","unstructured":"Pentsova E, Deangelis LM, Omuro A: Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neurooncol 2014; 117: 161\u20135","DOI":"10.1007\/s11060-014-1370-0"},{"key":"10.3238\/arztebl.2018.0419_ref60","doi-asserted-by":"crossref","unstructured":"Kasenda B, Ihorst G, Schroers R, et al.: High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma\u2014a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia 2017; 31:2623\u20139","DOI":"10.1038\/leu.2017.170"},{"key":"10.3238\/arztebl.2018.0419_ref61","doi-asserted-by":"crossref","unstructured":"Soussain C, Choquet S, Fourme E, et al.: Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica 2012; 97: 1751\u20136","DOI":"10.3324\/haematol.2011.060434"},{"key":"10.3238\/arztebl.2018.0419_ref62","doi-asserted-by":"crossref","unstructured":"Zhang JP, Lee EQ, Nayak L, et al.: Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. J Neurooncol 2013; 115: 71\u20137","DOI":"10.1007\/s11060-013-1196-1"},{"key":"10.3238\/arztebl.2018.0419_ref63","doi-asserted-by":"crossref","unstructured":"Fischer L, Thiel E, Klasen HA, et al.: Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006; 17: 1141\u20135","DOI":"10.1093\/annonc\/mdl070"},{"key":"10.3238\/arztebl.2018.0419_ref64","doi-asserted-by":"crossref","unstructured":"Nayak L, Abrey LE, Drappatz J, et al.: Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma 2013; 54: 58\u201361","DOI":"10.3109\/10428194.2012.698736"},{"key":"10.3238\/arztebl.2018.0419_ref65","doi-asserted-by":"crossref","unstructured":"Herrlinger U, Brugger W, Bamberg M, Kuker W, Dichgans J, Weller M: PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 2000; 54: 1707\u20138","DOI":"10.1212\/WNL.54.8.1707"},{"key":"10.3238\/arztebl.2018.0419_ref66","doi-asserted-by":"crossref","unstructured":"Mappa S, Marturano E, Licata G, et al.: Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Hematol Oncol 2013; 31: 143\u201350","DOI":"10.1002\/hon.2037"},{"key":"10.3238\/arztebl.2018.0419_ref67","doi-asserted-by":"crossref","unstructured":"Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS: Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005; 23: 1507\u201313","DOI":"10.1200\/JCO.2005.01.161"},{"key":"10.3238\/arztebl.2018.0419_ref68","doi-asserted-by":"crossref","unstructured":"Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE: Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 2007; 69: 1178\u201382","DOI":"10.1212\/01.wnl.0000276986.19602.c1"},{"key":"10.3238\/arztebl.2018.0419_ref69","doi-asserted-by":"crossref","unstructured":"Korfel A, Schlegel U, Herrlinger U, et al.: Phase II trial of temsirolimus for relapsed\/refractory primary CNS lymphoma. J Clin Oncol 2016; 34: 1757\u201363","DOI":"10.1200\/JCO.2015.64.9897"},{"key":"10.3238\/arztebl.2018.0419_ref70","doi-asserted-by":"crossref","unstructured":"Rubenstein JL, Formaker P, Wang X, et al.: Lenalidomide is highly active in recurrent CNS lymphomas: phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide as maintenance monotherapy. JCO 2016; 34(Suppl): 7502.","DOI":"10.1200\/JCO.2016.34.15_suppl.7502"},{"key":"10.3238\/arztebl.2018.0419_ref71","doi-asserted-by":"crossref","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, et al.: Inhibition of B cell receptor signaling by Ibrutinib in Primary CNS Lymphoma. Cancer cell 2017; 31: 833\u201343 e5.","DOI":"10.1016\/j.ccell.2017.04.012"},{"key":"10.3238\/arztebl.2018.0419_ref72","doi-asserted-by":"crossref","unstructured":"Nayak L, Iwamoto FM, LaCasce A, et al.: PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma. Blood 2017; 129: 3071\u20133","DOI":"10.1182\/blood-2017-01-764209"},{"key":"10.3238\/arztebl.2018.0419_ref73","doi-asserted-by":"crossref","unstructured":"Fritsch K, Kasenda B, Schorb E, et al.: High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia 2017; 31: 846\u201352","DOI":"10.1038\/leu.2016.334"},{"key":"10.3238\/arztebl.2018.0419_ref74","doi-asserted-by":"crossref","unstructured":"Omuro A, Chinot O, Taillandier L, et al.: Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. The Lancet Haematology 2015; 2: e251\u20139","DOI":"10.1016\/S2352-3026(15)00074-5"},{"key":"10.3238\/arztebl.2018.0419_ref75","doi-asserted-by":"crossref","unstructured":"Kurzwelly D, Glas M, Roth P, et al.: Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol 2010; 97: 389\u201392","DOI":"10.1007\/s11060-009-0032-0"},{"key":"10.3238\/arztebl.2018.0419_ref76","doi-asserted-by":"crossref","unstructured":"Fend F, Ferreri AJ, Coupland SE: How we diagnose and treat vitreoretinal lymphoma. Br J Haematol 2016; 173: 680\u201392","DOI":"10.1111\/bjh.14025"},{"key":"10.3238\/arztebl.2018.0419_ref77","doi-asserted-by":"crossref","unstructured":"Grimm SA, Pulido JS, Jahnke K, et al.: Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group report. Ann Oncol 2007; 18: 1851\u20135","DOI":"10.1093\/annonc\/mdm340"},{"key":"10.3238\/arztebl.2018.0419_ref78","doi-asserted-by":"crossref","unstructured":"Riemens A, Bromberg J, Touitou V, et al.: Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. JAMA Ophthalmol 2015; 133: 191\u20137","DOI":"10.1001\/jamaophthalmol.2014.4755"},{"key":"10.3238\/arztebl.2018.0419_ref79","doi-asserted-by":"crossref","unstructured":"Grimm SA, McCannel CA, Omuro AM, et al.: Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group report. Neurology 2008; 71: 1355\u201360","DOI":"10.1212\/01.wnl.0000327672.04729.8c"},{"key":"10.3238\/arztebl.2018.0419_ref80","doi-asserted-by":"crossref","unstructured":"Skiest DJ, Crosby C: Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 2003; 17: 1787\u201393","DOI":"10.1097\/00002030-200308150-00007"},{"key":"10.3238\/arztebl.2018.0419_ref81","doi-asserted-by":"crossref","unstructured":"Cavaliere R, Petroni G, Lopes MB, Schiff D, International Primary Central Nervous System Lymphoma Collaborative Group: Primary central nervous system post-transplantation lymphoproliferative disorder: an International primary central nervous system lymphoma collaborative group report. Cancer 2010; 116: 863\u201370","DOI":"10.1002\/cncr.24834"},{"key":"10.3238\/arztebl.2018.0419_ref82","doi-asserted-by":"crossref","unstructured":"Wieters I, Atta J, Kann G, et al.: Autologous stem cell transplantation in HIV-related lymphoma in the rituximab era\u2014a feasibility study in a monocentric cohort. J Int AIDS Soc 2014; 17: 19648","DOI":"10.7448\/IAS.17.4.19648"},{"key":"10.3238\/arztebl.2018.0419_ref83","doi-asserted-by":"crossref","unstructured":"Pulczynski EJ, Kuittinen O, Erlanson M, et al.: Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica 2015; 100: 534\u201340","DOI":"10.3324\/haematol.2014.108472"},{"key":"10.3238\/arztebl.2018.0419_ref84","doi-asserted-by":"crossref","unstructured":"Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G: Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma\u2014a long-term follow-up study. Ann Oncol 2012; 23: 2670\u20135.","DOI":"10.1093\/annonc\/mds059"},{"key":"10.3238\/arztebl.2018.0419_ref85","unstructured":"NLLLN-Netzwerk Lymphome und lymphomatoide L\u00e4sionen des Nervensystems. http:\/\/pathologie-neuropathologie.uk-koeln.de\/institut-fuer-neuropathologie\/nllln (last accessed on 2 May 2018)."},{"key":"10.3238\/arztebl.2018.0419_ref86","unstructured":"AWMF: Prim\u00e4re ZNS-Lymphome. (last accessed on 2 May 2018)."},{"key":"10.3238\/arztebl.2018.0419_ref87","doi-asserted-by":"crossref","unstructured":"Ferreri AJ: How I treat primary CNS lymphoma. Blood 2011; 118: 510\u201322","DOI":"10.1182\/blood-2011-03-321349"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T06:08:54Z","timestamp":1751695734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,22]]},"references-count":87,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2018.0419","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,22]]}}}